Medical Tidbits, Stryker Corporation named one of Fortune magazine’s “100 Best Companies to Work For” for sixth consecutive year

Stryker Corporation (NYSE:SYK) announced today that it has been named as one of the Fortune’s 2016 100 Best Companies to Work For in its 19th annual survey of top-rated workplaces in the United States. The list recognizes companies that have exceptional workplace cultures. This is the sixth consecutive year Stryker has been named to the list, and the company was ranked 21 out of 100. The full list and related stories are available at http://fortune.com/best-companies/.

“It is an honor to be named one of the 100 Best Companies to Work For again this year,” said Katy Fink, Vice President, Human Resources. “This is a testament to our focus on people and our culture that invests in employee growth and development. We greatly appreciate the contributions of our employees, their drive to make healthcare better, and their passion in making Stryker a great place to work.”

Stryker is one of the world’s leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information at www.stryker.com.

Altan Pharma Announces Licensing Agreement for Generic of Antifungal Agent Caspofungin

DUBLIN–(BUSINESS WIRE)–Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that it has signed a licensing agreement to commercialise a generic version of caspofungin. The agreement covers the territories of Germany, France, Italy, Spain, the United Kingdom, Belgium, Portugal, Poland and Latin America.

Chairman and Chief Executive Officer of Altan Pharma, Guillermo Herrera stated: “Licensing the rights to generic caspofungin reflects a significant step forward for Altan as we continue to build a strong portfolio of injectable drugs which we can bring to the European and other markets. Altan are committed to building a deep and diverse pipeline through ongoing internal development, in-licensing and further acquisitions.” read more

GSK Names Winners of 2015 Discovery Fast Track Challenge

LONDON–(BUSINESS WIRE)–GSK has announced the winners of its third Discovery Fast Track Challenge. The programme is sponsored by GSK’s Discovery Partnerships with Academia (DPAc) group to provide an opportunity for academic researchers in Europe and North America to collaborate with GSK and explore novel ideas for potential medicines. Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America. The selected proposals cover research related to discovery of potential new treatments for cancer, inflammatory bowel disease, HIV and kidney disease. read more

GORE® EXCLUDER® Iliac Branch Endoprosthesis Gains FDA Approval

FLAGSTAFF, Ariz.–(BUSINESS WIRE)–At the Houston Aortic Symposium today, W. L. Gore & Associates, Inc. (Gore) announced the Food and Drug Administration (FDA) approval of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE), making it the first off-the-shelf aortic branch device approved in the United States and the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms. The first-of-its-kind device is a complete, fully engineered system (Gore designed iliac branch and internal iliac components), which received CE Mark in 2013. read more

Khloé Kardashian Kicks Off Allergan Live Chin Up Campaign at New York City Event

PRNewswire/ — Allergan plc (NYSE: AGN) a leading global pharmaceutical company, kicked off their Live Chin Up campaign at an exclusive event at the Frank Gehry-designed IAC Building in New York City today, hosted by television personality and New York Times best-selling author Khloé Kardashian. The Live Chin Up campaign is designed to help encourage people to not let the things that bother them get in their way.  read more

New Data Presented at WORLDSymposium™ 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma™ (sebelipase alfa)

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new two-year data from an ongoing, open-label Phase 2/3 trial of Kanuma (sebelipase alfa) in infants with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease. Data from this study demonstrated a substantial survival benefit (56 percent, or 5 out of 9) to beyond 2 years of age for patients with rapidly progressive LAL-D during infancy who were treated with Kanuma, with the longest-treated patient surviving to over 5 years of age read more

BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01

PRNewswire/ — BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women’s health, today announced that it will immediately commence a Phase 2a clinical study under its U.S. FDA Investigational New Drug (IND) application for BPX-01, a hydrophilic formulation of the well-established drug minocycline.  This clinical study will assess effectiveness in reducing the number of acne-causing bacteria in study patients at four weeks and evaluate the drug’s safety and tolerability.  This is the first clinical study in the clinical development program for BPX-01. read more

Allergan Launches Bold Access To LILETTA® (levonorgestrel-releasing intrauterine system)    

LILETTA is a hormone-releasing system placed in a woman’s uterus to prevent pregnancy for up to three years and is greater than 99% effective. The LILETTA + LILETTA Patient Commitment Program was designed for eligible patients with commercial insurance who receive LILETTA on or before December 31, 2016. When the time comes, eligible patients wishing to continue with LILETTA may obtain a second LILETTA product at no out-of-pocket cost, up to a maximum savings limit of $700.* read more

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of the formulation patent owned by Debiopharm (Patent N- 4430229) related to Elplat® (Oxaliplatin) Drip Infusion of 50, 100 and 200 mg a treatment drug for cancer.

The Court ruled that the sale of the generic version of the cancer drug by Nippon Kayaku Co., Ltd. (Nippon Kayaku) infringed Debiopharm’s Japanese patent.

Debiopharm filed a patent infringement law suit with the Tokyo District Court on May 8th, 2015 against Nippon Kayaku, the distributor of the generic version of Elplat® treatment. In accordance with this judgement, a provisional disposition order was issued for the company to suspend the distribution of products. Twelve other pending infringement actions were also filed by Debiopharm against all the generics companies that started to commercialize their generic version of Elplat® in 2015.

Norgine Reinforces Its Commitment to Improving the Detection of Colorectal Cancer

Norgine B.V. today announces that it is supporting the March 2016 European Colorectal Cancer awareness campaign. Colorectal cancer is the second most common cause of cancer-related mortality in the world[1], with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe. [2],[3]

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.